GlassScriptPhysician profile
Consuelo Tomas
NPI 1497590103
$2,322.37
in general payments reported to CMS, 2019-2025
11 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $528 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $498.91 | 2024-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $402.59 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $250.99 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $242.35 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.69 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $202.94 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $136.75 | 2024-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $123.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.77 | 2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $95.16 | 2025 | Cobenfy |
| Alkermes, INC. | $38.19 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Consuelo Tomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.